Benjamin De Becker, Nicolas Derval, Reshma Amin, Milad El Haddad, Thomas Pambrun, Benjamin Bouyer, Clara François, Maarten De Smet, El Mehdi Channan, Nicolas Blankoff, Olaf Krahnefeld, Tolga Agdirlioglu, Damien Minois, Antoine Andorin, Francis Bessière, Kévin Gardey, Henry W. Sesselberg, Jordan Leyton‐Mange, Hugo Marchand, Claude Jean Mariottini, Manel Miled, F. Sébag, Nicolas Lellouche, Marian Andronache, Procolo Marchese, Andrea Rossi, Martina Nesti, J. Herzet, Moisés Rodríguez‐Mañero, Nikola Pavlović, Frédéric Anselme, Corentin Chaumont, Adrianus P. Wijnmaalen, Sebastiaan R.D. Piers, Johan Waktare, Ali Najm, Alexandre Almorad, Pedro A. Sousa, Caroline Lepièce, Damien Badot, N. Auquier, Michalis Efremidis, Evgeny Lyan, Vera Maslova, René Tavernier, Mattias Duytschaever, Jean‐Benoît le Polain de Waroux, Miguel Valderrábano, Sébastien Knecht
BACKGROUND: Retrograde ethanolization of the vein of Marshall (VOM) has been identified as an adjunct technique in the treatment of persistent atrial fibrillation (AF) and left atrial tachycardia, as stated in the last consensus statement on ablation of AF. However, there is a lack of high-volume data on the technique. METHODS: Through the collection of data from worldwide centers, we performed this international survey that aims to analyze the safety and procedural characteristics of VOM ethanolization in patients referred for treatment of AF or left atrial tachycardia. RESULTS: We included 5579 patients (66 years; range, 20-93) from 26 centers, who underwent VOM ethanolization between 2008 and 2024 for persistent AF (81%), paroxysmal AF (9%), or left atrial tachycardia (10%) under deep sedation (53%) or general anesthesia (47%). A concomitant mitral isthmus line was attempted in 79% of the cases, achieving mitral isthmus block in 98% of patients. There were 0.92% of periprocedural serious adverse events, including 0.09% of peri-procedural death (5 patients). Three patients developed hemodynamic collapse immediately after VOM ethanolization, causing the death of 1 due to anaphylactic shock. One patient died following surgical drainage of pericardial effusion 3 weeks after the procedure. The 3 other deaths were not directly related to VOM ethanolization. Pericardial effusion was observed in 123 patients (2.2%) at the time of or immediately after the procedure, requiring drainage in 20 patients (0.36%) and later in 32 additional patients (0.57%), including 5 (0.09%) requiring drainage. Pacemaker implantation was required in 2 patients (0.04%), 1 for high-grade atrioventricular block and 1 for sinus node dysfunction. CONCLUSIONS: This international survey shows that VOM ethanolization is predominantly performed in patients with persistent AF. It is associated with rare but potentially life-threatening adverse events. Mitral isthmus line ablation results in a very high rate of block when performed concomitantly.